-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 T+UsMJJSzixfCq9kprNWpLzM/AO+h0HcvdLTd21lER2VhanChNGcfi/izN7ScjRe
 0r17OOZfxUX7HEK6iwCJDA==

<SEC-DOCUMENT>0001193125-09-002750.txt : 20090108
<SEC-HEADER>0001193125-09-002750.hdr.sgml : 20090108
<ACCEPTANCE-DATETIME>20090107213726
ACCESSION NUMBER:		0001193125-09-002750
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090107
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090108
DATE AS OF CHANGE:		20090107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NUVELO INC
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		09514359

	BUSINESS ADDRESS:	
		STREET 1:		201 INDUSTRIAL ROAD
		STREET 2:		SUITE 310
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070-6211
		BUSINESS PHONE:		650-517-8000

	MAIL ADDRESS:	
		STREET 1:		201 INDUSTRIAL ROAD
		STREET 2:		SUITE 310
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070-6211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Date of earliest event reported: January&nbsp;7, 2009 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>Nuvelo, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>201 Industrial Road, Suite 310, San Carlos, CA 94070-6211 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>(650) 517-8000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>N/A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former Name or Former Address,
if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;8.01 Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Stockholder Meeting </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">A special meeting of the stockholders of Nuvelo, Inc. (the &#147;Company&#148;) was held on Wednesday, January&nbsp;7,
2009 to consider matters related to the proposed merger among the Company, Dawn Acquisition Sub, Inc., a wholly-owned subsidiary of the Company, and ARCA biopharma, Inc. (&#147;ARCA&#148;), pursuant to that Agreement and Plan of Merger and
Reorganization, dated September&nbsp;24, 2008, by and among the Company, Dawn Acquisition Sub, Inc., and ARCA, as amended on October&nbsp;28, 2008 (the &#147;Merger&#148;). The stockholders of the Company voted to approve the issuance of Company
common stock in the Merger, and also to adjourn the meeting until January&nbsp;23, 2009 to solicit additional proxies in favor of a proposal to amend the Company&#146;s amended and restated certificate of incorporation to effect a reverse stock
split of the issued and outstanding shares of the Company&#146;s common stock (the &#147;Reverse Split&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The special meeting of the stockholders of
the Company will reconvene at 9:00 a.m. Pacific time on January&nbsp;23, 2009 at Nuvelo&#146;s corporate headquarters located at 201 Industrial Road, Suite 310, San Carlos, California to consider the proposal to approve the amendment of the
Company&#146;s amended and restated certificate of incorporation to effect the Reverse Split. This proposal is a necessary condition to completion of the proposed Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Nuvelo has elected to withdraw a proposal to amend its amended and restated certificate of incorporation to increase the number of authorized shares of the Company&#146;s common stock to 250 million. Approval of this
proposal is not a necessary condition to completion of the proposed Merger. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Additional Information about the Merger and Where to Find It
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company has filed a registration statement on Form S-4, and a related proxy statement/prospectus/consent solicitation, as amended, in connection
with the proposed Merger. Investors and security holders are urged to read the registration statement on Form S-4 and the related proxy statement/prospectus/consent solicitation. Investors and security holders may obtain free copies of these
documents and other documents filed with the SEC at the SEC&#146;s website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting Nuvelo Investor Relations at the email
address: ir@nuvelo.com or by phone at 650-517-8000. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Participants in the Solicitation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Nuvelo, ARCA and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Nuvelo in connection with the Merger. Information regarding
the special interests of these directors and executive officers in the Merger is included in the proxy statement/prospectus/consent solicitation described above. Additional information regarding the directors and executive officers of Nuvelo is also
included in Nuvelo&#146;s definitive proxy statement for its 2008 Annual Meeting of Stockholders which was filed with the SEC on April&nbsp;23, 2008 and its Annual Report on Form 10-K for the year ended December&nbsp;31, 2007, which was filed with
the SEC on March&nbsp;12, 2008. These documents are available free of charge at the SEC&#146;s web site at www.sec.gov and from Investor Relations at Nuvelo as described above. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">(d)&nbsp;Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press Release, dated January 7, 2009, entitled &#147;Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement with ARCA biopharma&#148;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Nuvelo, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Lee Bendekgey</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">Senior Vice President, Chief Financial
Officer and General Counsel</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dated: January&nbsp;7, 2009 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit Index </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press Release, dated January 7, 2009, entitled &#147;Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement with ARCA biopharma&#148;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
FACE="Times New Roman" SIZE="2">Filed by Nuvelo, Inc. Pursuant to Rule 425 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Under the Securities Act of 1933 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">And Deemed Filed Pursuant to Rule 14a-12 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Under
the Securities Exchange Act of 1934 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Subject Company: ARCA biopharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">Commission File No. 333-154839 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top">

<IMG SRC="g88810g88d85.jpg" ALT="LOGO"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="3"><B>PRESS RELEASE</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Contact:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">SVP and Chief Financial
Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Nuvelo</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">650-517-8358</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">lbendekgey@nuvelo.com</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Danielle Bertrand</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">WeissComm Partners</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">415-946-1056</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">dbertrand@wcpglobal.com</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO SHAREHOLDERS APPROVE ISSUANCE OF COMMON STOCK </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PURSUANT TO MERGER AGREEMENT WITH ARCA BIOPHARMA </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><I>Nuvelo Stockholder Meeting to Reconvene January&nbsp;23, 2009 to Consider Reverse Stock Split </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><I>Necessary to Consummate Transaction </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>San Carlos, California, January&nbsp;7, 2009</B> &#150;Nuvelo, Inc. (Nasdaq: NUVO) today announced
that the stockholders of Nuvelo have approved the issuance of Nuvelo Common Stock pursuant to the merger agreement dated September&nbsp;24, 2008, as amended, between Nuvelo, ARCA biopharma and a Nuvelo subsidiary. Nuvelo&#146;s stockholders also
voted to adjourn Nuvelo&#146;s special stockholder meeting until January&nbsp;23, 2009, to solicit additional proxies in favor of a proposal to amend the Company&#146;s amended and restated certificate of incorporation to effect a reverse stock
split of the issued and outstanding shares of Nuvelo&#146;s common stock. This proposal is a necessary condition to the completion of the proposed merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">A substantial majority of the proxies received by Nuvelo to date reflect votes cast in favor of both the proposal regarding the reverse stock split and a separate proposal to amend the Company&#146;s amended and restated certificate of
incorporation to increase the number of authorized shares of Nuvelo common stock to 250 million. However, approval of each of these proposals requires the affirmative vote of a majority of the issued and outstanding shares of Nuvelo&#146;s common
stock, which was not received by the time of the stockholder meeting. As the proposal relating to the stock split is a necessary condition to the completion of the proposed merger, while the proposal relating to the increase in authorized shares of
Nuvelo common stock is not, the Board of Directors of Nuvelo has withdrawn the proposal to increase the number of authorized shares and the special stockholder meeting has been adjourned to a later date to solicit additional proxies on the proposal
authorizing the reverse stock split. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Nuvelo stockholder meeting will reconvene at 9:00 a.m. PST on January&nbsp;23, 2009 at Nuvelo&#146;s corporate
headquarters located at 201 Industrial Road, Suite 310, San Carlos, California to consider the proposal to approve the amendment of the Company&#146;s amended and restated certificate of incorporation to effect the reverse stock split. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Shareholders who need assistance with voting their shares should contact Nuvelo&#146;s proxy solicitor, Georgeson Inc., at 800-377-0321. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About Nuvelo </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Nuvelo,
Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo&#146;s development pipeline
includes NU172, a direct thrombin inhibitor which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator in Phase 1 development for the potential
treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand
its pipeline and create additional partnering and licensing opportunities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Information about Nuvelo is available at its website at http://www.nuvelo.com
or by phoning 650-517-8000. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Forward-looking statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">This press release contains &#147;forward-looking statements&#148; which include, without limitation, statements regarding the completion of the proposed merger transaction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc., the
solicitation of proxies, the transaction&#146;s anticipated completion and the progress of Nuvelo&#146;s clinical stage and research programs, which statements are hereby identified as &#147;forward-looking statements&#148; for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on the companies&#146; managements&#146; current expectations and involve risks and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, failure of Nuvelo&#146;s stockholders to approve the proposal regarding the reverse stock split, the ability to complete
the transaction contemplated by this communication in a timely fashion, the risk that Nuvelo&#146;s and ARCA&#146;s business operations will not be integrated successfully; the combined company&#146;s inability to further identify, develop and
achieve commercial success for products and technologies; the risk that the combined company&#146;s financial resources will be insufficient to meet the combined company&#146;s business objectives; uncertainties relating to drug discovery and the
regulatory approval process; clinical development processes; enrollment rates for patients in the companies&#146; clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of
critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo&#146;s filings with the SEC, including without
limitation Nuvelo&#146;s quarterly report on Form 10-Q for the quarter ended September&nbsp;30, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Additional Information and Where to Find It </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Nuvelo has filed a
registration statement on Form S-4, and a related proxy statement/prospectus/consent solicitation, in connection with the merger. Investors and security </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">holders are urged to read the registration statement on Form S-4 and the related proxy statement/prospectus/consent solicitation because they contain
important information about the merger transaction. Investors and security holders may obtain free copies of these documents and other documents filed with the SEC at the SEC&#146;s website at http://www.sec.gov. In addition, investors and security
holders may obtain free copies of the documents filed with the SEC by contacting Nuvelo Investor Relations at the email address: ir@nuvelo.com or by phone at 650-517-8000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">In addition to the registration statement and related proxy statement/prospectus/consent solicitation, Nuvelo files annual, quarterly and special reports, proxy statements and other information with the SEC. You may
read and copy any reports, statements or other information filed by Nuvelo, Inc. at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information. Please call the SEC at
1-800-SEC-0330 for further information on the public reference room. Nuvelo, Inc.&#146;s filings with the SEC are also available to the public from commercial document-retrieval services and at SEC&#146;s website at http://www.sec.gov, and from
Investor Relations at Nuvelo as described above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Nuvelo, ARCA and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Nuvelo in connection with the merger transaction. Information
regarding the special interests of these directors and executive officers in the merger transaction is included in the proxy statement/prospectus/consent solicitation described above. Additional information regarding the directors and executive
officers of Nuvelo is also included in Nuvelo&#146;s proxy statement for its 2008 Annual Meeting of Stockholders which was filed with the SEC on April&nbsp;23, 2008 and its Annual Report on Form 10-K for the year ended December&nbsp;31, 2007, which
was filed with the SEC on March&nbsp;12, 2008. These documents are available as described above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g88810g88d85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g88810g88d85.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!*`0D#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HK
MAOB?XDFT+0X(;.9HKRYE&UEZJJD$G\\#\36_X5\0P^)=!@OXR!+C9/&/X)!U
M'T[CV-9JK%U'3ZG;/`5HX6.+:]UMK^O77[C3N[VVL+9KB[N(X(5^\\C!0/SK
MSW6/BM;M=)I_AZW-U<2N(UGE!"`DX&!U;]*X_P")VEZQ8:]YU[=SW=C.2UM(
MYX3U3`X!'ZC\:J_#+33J/C:T8J3':AIV]L#`_4BN&IBJCJ>RBK'T^"R/!T\&
M\=6ESI)NVR].[UTZ>A]`H&"*'.6`Y..IIU<#\4?$-_H.FZ?_`&;=-;SRSDEE
M`.54=#GMDBN7TGXQZA!M35;&*Y7O)"?+?\N0?TKIGBJ<)\DCQ</D.,Q6&6)H
MI-.^E[/3\/Q/9J*Y'1OB1X=UATA6Y>VN'("Q7"8))[`C(_6NNK>$XS5XNYYF
M(PM;#RY*T7%^844451@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`455U#4;32K0W5].L$"D`R-G`).!GTYIMIJNG7ZAK.^
MMIP>GE2JW\C2YE>Q:I3<>>SMWZ'B/Q+N-0U;Q9.19W(M;4>1"3$VTXZD<=SG
M\`*K?#_Q._ACQ`([HE+&Z(CG#<;#V?\`#//L37T'44EM;R_ZR")\_P!Y`:XG
MA)>T]HI:GTT.(J7U/ZG4H7C:V_X[;WU]2GK6CV?B'2);"[4/#*,JXZJ>S#WK
MD/AOX1NO#=WK#7R?O#(L,3@<.@YW#V.1^5=^JA5"J`%`P`.U+75*E&4U-[H\
M.ECZU/#SPT7[DK?@_P!>IXQ\9KOS-;TZT!_U5NSD>[-C_P!EKE_#/@C5_$[A
M[>+R;/.&N91A?P_O'Z5[->^!=.U;Q1)K6J$W("JD-L1A%`'\7][G)QT^M7/$
M'B;2O">GA[IE5MN(;:,#<^.P'8>_2N*>%4JDJE5V1]+AL]E1PE+!8&'-4MOV
M;U=EU]=O4@\,^"-(\,1AK>+SKLCYKF4`M^']T?2NDKQ?0_B;J-YXVMYM0D$6
MG3?N/(4_)$&/#>Y!QD^F:]HKIP]2G.-J:LD>'G&$Q>'K)XMWE)7OO\OEY:!7
M%_%3Q+J/A/P+<ZMI3QI=QRQHID0,,,V#P:[2O-/CS_R2N]_Z^(?_`$,5T'DF
M7\)?B^WBV=]%U]H8]6Y:WD1=BSKW7'9A^H^E>OU\@R^`[V#X<:-XZT1IO-B9
MS>*A.Z(I(=LJ^@&!GTP#ZX]Z^%/Q*@\<Z/\`9KQDCUNU0?:(QQYJ]/,4>_<=
MC[$4`=SJEQ)::1>W,1`DB@>1"1D9"DBO,_@KX]UWQNFM'6I89/LAA$7E1!,;
MM^<XZ_=%>E:RADT/4$!P6MI!GZJ:\/\`V9_]7XE^MM_[4H`]]HKSGQ'\7;#P
MYXXC\+S:7<S3N\*"9'4+^\QC@\\9KT:@`HKS_P`?_%6Q\`:G9V5UIES=M<Q&
M56B=5`YQCFK'C_XD0^`(K":ZTFYN[>\W`2Q.H",,':<]\'/X&@#N**S?#^MV
MOB/0+'6+(G[/=Q"10>J^JGW!R#]*EU?5+;1-'O-4O&VV]K$TLA[X`S@>YZ4`
M7:*Y3P%XV3QWH\VJ0:9/96R2^4AF<'S"!DD8[#('_P"JL#QQ\9='\)WYTFQM
MI-6U<':T$+86-O[K-@_-[`'WQ0!Z517B%Q\9?&FDP1WVL?#^>#3SRTA\Q,#Z
ME2!^->D^"_'>C>.M->[TJ1UDB($]M*,21$],CN#S@CTH`X'XS_$;Q#X)U?2[
M;19H(X[B!I)/,A#DD-CO7KEC*]QI]M-)C?)$KMCU(!KYX_:4_P"1AT/_`*]'
M_P#0Z^A-*_Y!%E_UPC_]!%`%NBO,_&?QETSPYJIT32;*;6M8#;&@@.%1_P"Z
M2`26]@#^%8E[\6/'6A0)?ZY\/Y(-.!'F2)*V5'N<';^.*`/9Z*YKP9XYT;QS
MI9O-*E8/'@3V\@Q)$3ZCN/0C@U+K7BA]'UFQTT:-?7;7N1%+`8]N0"6!W,#P
MHSTH`Z"BN.\._$C1O$VI6-C8Q7(FN[>6X`D4#RQ&^PAN>I/(QVKL:`*FIZ?!
MJVF7-A<KF&>,HWMGO]1UKYCU*PN-'U6YL9\K-;R%"1WQW'UZU]3UR6M?#_2]
M=\3Q:O>,Q18PLENO`E8="3Z8XQ["N/%X=U4G'<^CX?SB&`E.-;X&K_-?Y_Y'
MG7@33_%^LS+)::M>6>G(WSSNY93[*IX)_05[?$ACB1&D:0J`"[8RWN<5D:QK
M^C>$]/0W<L=O&JXBMXE^9AZ*H_\`U5F>"O%EQXMDU&Y-NMO9PND<*=6/4DL?
MRX%51C"DU3O=LQS*IB,PC+%JFHTX^5MW;?=O\$=;129&<9Y]*J:GJMEHUI]K
MU"<00;@I<J2`3TS@<5TMI*[/$A"4Y*,5=LYWQMXON/#MKY5AIUQ<W;KQ+Y3&
M*/W)QR?:O!-0U"[U2]DN[Z=Y[AS\SN>?I[#VKZ-A\9>&Y\!-;LLGLTH7^=)<
M0^%M8!$XTFZ+=R8V/Y]:XJ]%UG=3^1]3E691RR/+/#.[WEU_%?J?--?17P_U
M_P#M_P`*V\DC9N;?]Q/SR2!P?Q&#]<U4O/A?X5O@6BMI+<G^*WF./R.14WA;
MP,OA/4IY[+4II;6=-LD$J#J/NG([CGMWJ,-AZM&=]TS?.<WP&987E5XSCJKK
M[UI<ZZO-/CS_`,DKO?\`KXA_]#%>EUYI\>?^25WO_7Q#_P"ABO1/C2?X*QI+
M\)-+CD171_.5E89!!D;((KR;XA^#-2^%?BNW\5>%S)%IK2[D(&1;N>L;>J$=
M,_3Z^M_!'_DE&D_[TW_HQJ[?4]-L]8TRXTZ_@6>TN$,<L;="#_(^_:@#E_"W
MC>P\=>![C4+4K'<I;LEW;9R89-IX^A['O]0:\U_9G_U?B7ZVW_M2N/UG3-;^
M"7CAYK4O/I-XCI&6.%N(CU1O1UR/T/0XKL/V9_\`5^)?K;?^U*`.<^*/_)P-
MI_UWLO\`V6OJ"OF'XI*5_:`LR1PTUD1^:C^E?3U`'S=^TA_R->A_]>;?^AFO
M8/B+X57Q?X`O-/5-UTD8GM2!D^:HR`/J,K^->/\`[2'_`"-6A_\`7FW_`*&:
M^CHO]2G^Z*`/#_V=?$YFT[4/#%S(?-MF^TVZM_<)PX'T;!_X%5WX^:[/)8Z7
MX-T[+WNJS*TB+U*!L(/Q?_T$UQOBB(_"WX[6VLQ!H],O9/M#;5R/+D.)5_`Y
M('^[6]\/XG^(GQCU?QG.I;3M.;R[/<.,X*Q_DN6/N10!Z!J*I\,O@].ED1YN
MG66Q'_O3-QO_`.^VS7C_`,%-2\)Z/<ZAX@\3:M;1ZJ\FRW%P2S*#R[]#R2<9
MZ\'UKV/XOV,FH?"O78HLEDB6;`&>$=7/Z`UY7\!]#\*^)=)U2RUC2;.[U"VF
M$JM,F6,3#''L"I_.@#UB3XI>`I8VCD\1V#HP*LK9((/8C%>(>$M2T[P[\?DB
M\-WBSZ+?3^0OE$["DB@A?^`N1_WS7NO_``J_P/\`]"QI_P#W[J./P=X"T+6=
M.*:1IMIJ,LI-G\N'9U&X[?<#F@#R']I3_D8=#_Z]'_\`0Z]A\4:Y)X;^%MWJ
ML!VSP6"^2?1V`53^!(->/?M*?\C#H?\`UZ/_`.AUZ5\3;.2]^"=^D08M'9PR
MD+Z*58_A@$_A0!PW[.>A17+:QXEN5\VZ606T4C\E21N<Y/<Y7GZ^M>]S11W$
M+PS1K)%(I5T89#`\$$>E>+_LW7T<GA75['</-AO!*5[[70`?JAKVN@#Y<\.,
M_P`//V@7TJV8K92W?V1D)X,,N"F?H2I_"OI:[TNUO;VRO)E8S6;.T)#8P74H
M<COP37S9JQ_X2#]II$MSN5-3B4E?2)5W?EL:OJ"@#F-$^'_A_P`/:HNHZ?;2
M)<JA0,TK-P553P?9!^M=/110`$X&:\O\8?%-K&62PT6W<3C(:XN(RNW_`'5/
M7ZG\C7J%5+_2[#5(3%?V<%RGI*@;'T]*RJQG*-H.QW9?7PU"KSXFGSKM?].O
MH?+UY>W6H73W-Y/)/.YRSR-DFO<?A):"W\&>=C#7%P[Y]AA?Z&F:M\)=`OMS
MV336$A[(V]/R/]#74:!I:^'?#EMI[S"06L9W2`8!Y))Q^-<>&PTZ=5RF?29W
MG>%QF!C1P]T[K2UM%?Y;V/-O&WC.ZT;XC0RV3;H[*%8I8\\2!OF8'\Q]"*](
MM[C3/%WAPNF)K*\C*LIZCU!]"#_*OG'6=0;5=:O;]SDW$S./8$\#\L5U/PU\
M1W^DZXME#;SW5G=,!+#$I8H?[X'MW]OPK*CBOWK4MF=V8Y"OJ-.I2TJ4TO*_
M5_.^J.<\1:'<>'=;N--N>3&<H_9T/1A68JEF"J"6)P`.]>]?$OPI_;VB?;;6
M/-_9@LN.LB?Q+_4?_7KS/X;:)_;/B^W:128+3_2)/3(/RC\\?D:QJX9QJJ"V
M>QZ>7YU"OE[Q,_B@O>7G_P`'H>U^%-&70?#5E8``2)&&E/JYY;]>/PK9HHKV
MXQ44DC\PJU95:DJD]V[OYA7!_&#1-2\0?#RZT_2K1[J[>:)EB0C)`8$]:[RB
MF9G%?"?2-0T+X<Z;I^J6KVUW$9-\3D9&78CI[&NUHHH`Q/%?A;3?&&@3Z1J<
M>8I.4D7[T3CHZ^X_7D5Y]\%O!>L>"M2\466J6[+&TD`M[@#Y)U'F?,OX$<=L
MUZY10!XK\:OAGJOB"^MO$GAZ-I[V&,1SVZ-AR%)*NGJ1G&.O3%5M*^*OQ$6T
MBTZ;P%=W6I*!&)VBEC5R!R6&W&?Q`KW.B@#YD\>_#_XC>(-1L=5U&U?4;V>(
MF6&V*B*S`;Y8UR?3D^YZGK7TS&"(D!ZA13J*`/-_C1X*G\7>#UDT^W,VIV$G
MFP(H^:13PZC\,'_@-;'PR\*?\(?X%L=/EC"7D@\^[]?-;J#]!A?PKL**`&2Q
M1SPO#*BO'(I5T89#`\$$5\Z:[\+_`!AX`\5-KW@7S+FTW$HD6&DC4GF-D/WU
M^F?P(S7T=10!X3;?%OXD7,(MH_`$K7I&!(;:94SZ[3_\574^`O!WB*7Q`_C'
MQQ<+)J[1F*TM%(VVB'KTX!(XP/4Y))X]-HH`\-^.W@SQ%XGUK29M%TJ:\CAM
MW21HRORDMG')%>RVUHLFB0V5W$&1K98I8VY!&W!!_6KM%`'SQ)X&\9?"?Q=)
MK/A*U;5M)ERKP("S>7G.QUZY'9AG^8K>U#XK^--6L#9:#X`U2UU&52/.N(V9
M(_<94`GZG'UKVFB@#R7X2_"JY\*7$OB#7W676IU(2,-O\@-RQ+=W/?'3GDYK
MUJBB@`HHHH`****`"L/Q>U[_`,(M?Q:?!)-=SQ^3&D8Y^;@GVP"36Y12DN9-
M&E&I[*I&I:]FG;T/(O#_`,'G;9/KUUL'4VUN<GZ%_P##\Z]/TO1M.T6V%OIU
MG%;Q]]@Y;ZGJ?QJ]165*A3I?"CMQV:XO&O\`?2T[+1?=_F%8NA^&;#0+O4;B
MR7:;V42,N.$`'W1[9)/XUM45JXIM-]#BC5G",H1>DM_.VH4444S,****`"BB
LB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
